EyeGene Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Won-Il Yoo

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	23.9yrs
CEO ownership	4.8%
Management average tenure	no data
Board average tenure	no data

Recent management updates

No updates

Recent updates

CEO

Won-Il Yoo

23.9yrs

Tenure

Mr. Won-Il Yoo has been Chief Executive Officer and President of EyeGene, Inc. since June 2000. Mr. Yoo has directed EyeGene's initial financing, set-up, recruiting, R&D and business development. He has ov...

EyeGene Management

Management criteria checks 0/4

Key information

Recent management updates

Recent updates

Full year 2023 earnings released: ₩975 loss per share (vs ₩1,210 loss in FY 2022)

New minor risk - Share price stability

Full year 2022 earnings released: ₩1,210 loss per share (vs ₩1,971 loss in FY 2021)

EyeGene Ordinary Shares Deleted from Other OTC

Does EyeGene (KOSDAQ:185490) Have A Healthy Balance Sheet?

New 90-day high: ₩15,400

EyeGene's (KOSDAQ:185490) Stock Price Has Reduced 51% In The Past Five Years

Is EyeGene (KOSDAQ:185490) Using Debt In A Risky Way?

New 90-day high: ₩15,850

New 90-day low: ₩10,800

EyeGene Inc. announced that it expects to receive KRW 22 billion in funding from a group of investors

New 90-day high - ₩13,100

CEO

Tenure